Cochrane Evidence Synthesis and Methods ►

Gut microbial biomarkers for predicting adverse outcomes in people with chronic kidney disease

This is a protocol for a Cochrane Review (prognosis). The objectives are as follows:

To (a) identify the gut microbial biomarkers in patients with CKD, on dialysis, and with kidney transplants; (b) determine whether these biomarkers are associated independently with adverse patient-relevant outcomes leading to progression of CKD stages 1 to 5; and (c) explore sources of heterogeneity.

Investigation of sources of heterogeneity between studies

We will explore potential sources of heterogeneity that may impact outcomes such as differences in study participation; stage of CKD (KDIGO 2013; Appendix 1); study design (cohort, case series, case study), timing of outcome measurements; units and instruments of outcome measurements; and length of follow-up.

This is a protocol.

Published:

12 January 2022

Authors:

Cooper TE, Au EH, Chung EYM, Tunnicliffe DJ, Craig JC, Gesualdo L, Howell M, Mannon P, Mannon R, Strippoli GFM, Teixeira-Pinto A, Tong A, Wong G

See the full Review on

the Cochrane Library

►

Was this helpful? Donate.

If you found this evidence helpful, please consider donating to Cochrane. We are a charity that produces accessible evidence to help people make health and care decisions.
Donate
Print
PDF
Citation
Cooper TE, Au EH, Chung EYM, Tunnicliffe DJ, Craig JC, Gesualdo L, Howell M, Mannon P, Mannon R, Strippoli GFM, Teixeira-Pinto A, Tong A, Wong G. Gut microbial biomarkers for predicting adverse outcomes in people with chronic kidney disease (Protocol). Cochrane Database of Systematic Reviews 2022, Issue 1. Art. No.: CD014786. DOI: 10.1002/14651858.CD014786.